Next-generation sequencing (NGS) assays indicated that the tumor lacked <i>KIT/PDGFRA/SDH/RAS-P</i> (<i>RAS</i> pathways, <i>RAS-P</i>) mutations, thereby classifying this patient as quadruple WT GIST (qGIST). This evidence concerns the gene PDGFRA and neoplasm.